{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombocytosis&page=3",
    "query": {
      "condition": "Thrombocytosis",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 243,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombocytosis&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thrombocytosis&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T13:11:54.317Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02226172",
      "title": "Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Glasdegib (PF-04449913)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2014-10-06",
      "completion_date": "2018-01-31",
      "has_results": true,
      "last_update_posted_date": "2019-01-17",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02226172"
    },
    {
      "nct_id": "NCT03972943",
      "title": "CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "CALR Gene Mutation",
        "Essential Thrombocythemia",
        "JAK2 Gene Mutation",
        "MPL Gene Mutation",
        "Obstructive Sleep Apnea Syndrome",
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "Continuous Positive Airway Pressure",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 8,
      "start_date": "2019-05-15",
      "completion_date": "2023-07-28",
      "has_results": false,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972943"
    },
    {
      "nct_id": "NCT01969838",
      "title": "Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-Polycythemia Vera Myelofibrosis",
        "Post-Essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Momelotinib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match momelotinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sierra Oncology LLC - a GSK company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 432,
      "start_date": "2013-12-06",
      "completion_date": "2019-05-02",
      "has_results": true,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Escondido, California • Stanford, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01969838"
    },
    {
      "nct_id": "NCT01340651",
      "title": "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Winter Park, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01340651"
    },
    {
      "nct_id": "NCT05835466",
      "title": "Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis (PMF)",
        "Post Essential Thrombocythemia Myelofibrosis (ET-MF)",
        "Post Polycythemia Vera Related Myelofibrosis (PV-MF)"
      ],
      "interventions": [
        {
          "name": "reparixin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-07-24",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 9,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Buffalo, New York + 4 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05835466"
    },
    {
      "nct_id": "NCT00004058",
      "title": "12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Precancerous/Nonmalignant Condition"
      ],
      "interventions": [
        {
          "name": "tetradecanoylphorbol acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Medicine and Dentistry of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-12",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2010-01-26",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004058"
    },
    {
      "nct_id": "NCT02953704",
      "title": "Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MPN (Myeloproliferative Neoplasms)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1469,
      "start_date": "2016-12-31",
      "completion_date": "2022-03-29",
      "has_results": false,
      "last_update_posted_date": "2022-05-13",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 114,
      "location_summary": "Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 111 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02953704"
    },
    {
      "nct_id": "NCT01773187",
      "title": "Pacritinib Versus Best Available Therapy to Treat Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        },
        {
          "name": "Best Available Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CTI BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 327,
      "start_date": "2013-01",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2020-09-29",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Morristown, New Jersey + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773187"
    },
    {
      "nct_id": "NCT01291784",
      "title": "Anti-TGF-beta Therapy in Patients With Myelofibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelofibrosis",
        "Primary Myelofibrosis",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Post-essential Thrombocythemia Related Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "monoclonal antibody to TGF-beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "John Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2011-02",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-12-08",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01291784"
    },
    {
      "nct_id": "NCT04896112",
      "title": "A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Primary Myelofibrosis",
        "Post-polycythemia Vera Myelofibrosis",
        "Post-essential Thrombocythemia Myelofibrosis",
        "Polycythemia Vera"
      ],
      "interventions": [
        {
          "name": "LNK01002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lynk Pharmaceuticals Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-04-08",
      "completion_date": "2022-10-20",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-06T13:11:54.317Z",
      "location_count": 2,
      "location_summary": "Farmington Hills, Michigan • Sterling Heights, Michigan",
      "locations": [
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Sterling Heights",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04896112"
    }
  ]
}